OBJECTIVE: To test whether excess weight gain in patients treated for childhood acute lymphoblastic leukaemia (ALL) was predictable using patient characteristics at diagnosis. DESIGN AND SUBJECTS: Longitudinal study of changes in body mass index (BMI) in all 98 patients treated in Scotland on treatment protocol MRC UKALL-XI who had reached at least 3 y post-diagnosis in ®rst remission. MEASUREMENTS: The in¯uence of the following variables on changes in BMI, expressed as a standard deviation score (SDS), was tested using variable selection techniques and classi®cation and regression trees: BMI SDS at diagnosis; age at diagnosis; gender; socioeconomic status; treatment. RESULTS: Prevalence of obesity (BMI SDSb2.0) was`2% at diagnosis, but increased to 16% at 3 y. Gain in BMI SDS was signi®cantly inversely in¯uenced by BMI SDS at diagnosis (P`0.01) and age at diagnosis (P`0.01). CONCLUSION: Obesity is common in ALL by the end of therapy, and is more likely in children who are younger and thinner at diagnosis. Excess weight gain was not readily predictable from routinely collected information available at diagnosis and so all children treated for ALL should be considered`at risk' of excess weight gain and the target of obesity prevention.
Introduction
Disease-free survival in childhood cancer has signi®-cantly improved in the last 20 y. 1 This has led to concern over the quality of survival and in particular to the adverse consequences of therapy. 2 In childhood acute lymphoblastic leukaemia (ALL) one major adverse outcome is obesity. Obesity is a general concern because of the adverse consequences. 3 In addition, there is speci®c concern in the context of ALL therapy that obesity might compound some of the other`late effects' described to date, including development of the`metabolic syndrome', 4 cardiac dysfunction, 5 and educationalapsychosocial dysfunction. 6 Obesity in ALL develops from a process of excess weight gain which begins during treatment 7 ± 9 and continues beyond the end of therapy. 7, 8, 10 The prevalence of obesity at ®nal height in the survivors of ALL is approximately 4 ± 5 times that expected, 10 ± 12 and this may underestimate the magnitude of the problem since standard weight for height indices underestimate prevalence of excess adiposity. 4, 13 Corticosteroids 9 and growth hormone insuf®-ciency following low-dose cranial irradiation (where it is still used 14 ) might contribute to excess weight gain in ALL, but the major cause of obesity on modern treatment protocols has recently been identi®ed as reduced habitual physical activity. 15, 16 The appropriate clinical response to excess weight gain in ALL is unclear: while prevention of obesity is more effective than treatment, and is possible in childhood, 3 it is uncertain whether the focus of prevention should be on patients with ALL deemed to be at particularly`high risk' of developing obesity, or on all patients treated for ALL. This will depend on the predictive value of any risk factors for obesity, but the extent to which patient characteristics can predict excess weight gain in ALL is unclear 12, 17 and has not been tested for modern treatment protocols. The main aim of this study was therefore to investigate whether one could predict high risk of excess weight gain in subsets of patients, based on patient characteristics routinely collected at diagnosis, using stepwise linear regression and`prognostic tree' methodology to identify sub-groups of patients at particularly high risk of excess weight gain. The latter has been useful in providing clinical guidance in other malignancies, but its potential use in obesity prevention has not been explored. 18 
Methods

Patients
Patients were drawn from all Scottish treatment centres. All were treated on the same protocol, MRC UKALL XI (1990 ± 1997) . 19 This protocol has been described in detail elsewhere, 19 but in summary it involved multi-agent chemotherapy to induce remission followed by two or three`intensi®cations' and 100 weeks of`maintenance' chemotherapy. Maintenance chemotherapy consisted of daily 6-mercaptopurine, weekly methotrexate (MTX), and four weekly treatment with vincristine and prednisolone. Patients were excluded from the study if they relapsed, had received testicular irradiation, had received growth hormone therapy, or had other conditions relevant to body composition and energy balance (eg Downs syndrome). All other Scottish patients treated on this protocol were considered for inclusion (n 126), but we analysed data only from those children who had reached 3 y post-diagnosis (n 98). Patients were allocated to central nervous system treatment on the basis of risk group at diagnosis: of the 126 patients, nine received 24 Gy of cranial irradiation; the rest did not received cranial irradiation but were randomly allocated to either high-dose intravenous MTX with continuing intra-thecal MTX (n 54) or continuing intra-thecal MTX (n 63). The study had the approval of the local ethics committee.
Procedures
Degree of excess weight gain was measured using changes in body mass index (BMI); weight (kg)aheight 2 (m 2 ). The BMI, when corrected for age and sex, is a reasonably good proxy for body fatness in childhood 20 and so is an index of overweight. In addition, the BMI has practical advantages of ease of calculation and dependence on simple measurements made carefully and routinely (for calculation of drug dosage). Expression of BMI relative to contemporary reference data is now widely recommended for clinical assessment of overweight and obesity in childhood. 21 ± 23 In this study, BMI was calculated from measurement of height (to 0.1 cm) and weight (to 0.1 kg) and then expressed as a standardized score (SDS) relative to contemporary UK reference data. 22 This standardized score, the BMI SDS, is independent of age and sex, and summarizes deviation from the population mean.
The in¯uence of the following potential explanatory variables on BMI SDS was assessed in those patients who had reached 3 y post-diagnosis: age at diagnosis (y); gender; socioeconomic status, using a standard Scottish categorization scheme 24 (Carstairs score: 1 ± 7; 1 least economically deprived; 7 most economically deprived) based on postal code; BMI SDS at diagnosis; and allocation for central nervous system treatment (cranial irradiation; high-dose intravenous MTX plus continuing intra-thecal MTX; continuing intra-thecal MTX).
Statistical analyses
Simple changes in BMI SDS from diagnosis of ALL were described using paired t-tests and 95% con®-dence intervals. Prevalence of obesity, de®ned here as BMI SDSb2.0, was calculated annually from diagnosis.
A generalized linear model (a lattice of hypotheses using all main effects and ®rst-order interactions) was used to investigate which combinations of the potential explanatory factors above signi®cantly in¯uenced the outcome variable of maximum gain in BMI SDS over the 3 y after diagnosis. The other approach to identifying subgroups at`high risk of excess weight gain' was based on CART (classi®cation and regression trees), previously illustrated in a prognostic context for malignant melanoma. 18 The CART procedure employs successive binary splitting of data to identify subgroups which, in this case, have distinctly (and signi®cantly) different predicted changes in BMI SDS.
Results
Descriptive data
Characteristics of patients at diagnosis are given in Table 1 . Data on changes in BMI SDS are summarized in Table 2 . Changes in BMI SDS did not differ signi®cantly between boys and girls. The prevalence of obesity was 2% at diagnosis, and this rose to 4% 1 y later, 9% 2 y later (at the end of therapy), and 16% at 3 y post-diagnosis.
Individual changes in BMI SDS across time ( Figure  1 ; Table 2 ) indicated that the BMI SDS rose steeply within the ®rst year of treatment and peaked in the second or third year thereafter ( Table 2) . As a simple *Statistically signi®cant change from diagnosis (paired t-test, P`0.01).
Obesity risk in ALL JJ Reilly et al summary measure of excess weight gain, the key outcome variable used in the subsequent analysis was the maximum change in BMI SDS from diagnosis over the ®rst 3 y from diagnosis. The effect of BMI SDS at diagnosis on this composite outcome variable is displayed in Figure 1 , where a general increase in BMI SDS over the ®rst 3 y is clearly seen across the full range of BMI SDS at diagnosis for both sexes.
The change was more marked in those patients at the lower end of the distribution of BMI SDS at diagnosis (Figure 1 ). This ®gure also removes any concern that using the maximum change would give rise to à regression to the mean' effect when this was related to BMI SDS at diagnosis (as this response is across the full range of BMI SDS at diagnosis). In addition, the response here is the maximum change over 3 y in the standardised BMI SDS, so any`mathematically forced' negative correlation arising over this period is further attenuated.
Analysis of risk factors for excess weight gain
Generalized linear modelling. Using a lattice of hypotheses approach to a generalized linear model based on the potential explanatory variables (and their ®rst-order interactions), the maximum change in BMI SDS was signi®cantly in¯uenced by, in descending order, BMI SDS at diagnosis (inversely related; P`0.01), age at diagnosis (inversely related, P`0.01), and the`interaction' between gender and BMI SDS at diagnosis (P`0.01). Effect sizes and further statistical summaries of the model are given in Table 3 . This`interaction' effect of gender on maximum change in BMI SDS was to modify the in¯uence of BMI SDS at diagnosis with a`less steep' slope of the regression of maximum change on BMI SDS at diagnosis for boys than girls. In the generalized linear model, socio-economic status (P 0.22) and central nervous system treatment allocation (P 0.83) had no signi®cant in¯uence on maximum changes in BMI SDS when the above signi®cant factors were corrected for: these variables were therefore not relevant for the prediction of maximum change in BMI SDS when the signi®cant factors were included in the ®nal model. In summary, this approach showed that those patients most at risk of excess weight gain were those who had lower BMI SDS at diagnosis, especially in the boys, and also those who were diagnosed with ALL at a younger age.
Classi®cation and regression trees. To con®rm these ®ndings, and allow the production of a`prognostic tool' to enable clinicians to target prevention on sub-groups of children at high risk of excess weight gain, a CART approach was applied to the data, resulting in the prognostic trees displayed in Figures 2 (boys) and 3 (girls). Overall, these con®rm the ®ndings of the generalized linear model with BMI SDS at diagnosis as the major, and indeed only, predictor of excess weight gain for boys, but for girls the high-risk subgroup(s) were de®ned by combinations of BMI SDS at diagnosis and age at diagnosis. The foot of each tree`branch' contains a node which gives the predicted gain in BMI SDS over 3 y in sub-categories of patients. This could be used to predict sub-groups of children at particularly high risk of excess weight gain. For boys, the highest risk of large gains in BMI SDS was for those with BMI SDS`À0.57 (`28th centile) at diagnosis. For girls, the sub-group at highest risk was characterized by Figure 1 Plot of maximum BMI SDS over 3 y from diagnosis against BMI SDS at diagnosis with boys and girls labelled separately (53 boys, 45 girls). Figure 2 Prognostic tree for change in BMI SDS in 53 boys treated for ALL. Numbers at each tree`branch' represent predicted gain in BMI SDS. Numbers in parentheses: (s.d., n).
Obesity risk in ALL JJ Reilly et al BMI SDS at diagnosis of`À1.05 (`14th centile), agè 5 y at diagnosis, and with a Carstairs socioeconomic deprivation score of at least 5.
Discussion
The aim of this study was to test for clinically useful predictors of excess weight gain in children treated for ALL on a modern treatment protocol. Identifying such factors might permit a targeted approach to prevention of excess weight gain and ultimately obesity in ALL. The statistical models revealed two factors (BMI SDS at diagnosis; age at diagnosis) which were inversely related to excess weight gain, and one factor (gender) which had a more complex in¯uence. For younger girls, greater levels of socioeconomic deprivation increased the risk of excess weight gain.
We tested for the in¯uence of factors which are routinely measuredacollected in ALL therapeutic protocols since these would most likely form the basis of any obesity screeningaprevention programme in ALL patients. This precluded assessment of other potentially important risk factors such as parental obesity. The variability in the relationship of the signi®cantly associated factors with excess weight gain (illustrated in Figure 1 ) represents an argument against a highly targeted approach to prevention. This, in turn, leads to the view that all children with ALL are at high risk of excess weight gain, and ultimately obesity. Monitoring all children treated for ALL for overweighta obesity is feasible using the BMI, since measurements of height and weight are made frequently and routinely. The same screening process could also be used to formally identify undernutrition in ALL, which is relatively common around the time of diagnosis. 25 In the absence of formal screening for under or overnutrition, abnormalities in nutritional status are rarely identi®ed in any specialty of paediatrics. 26 The prognostic trees shown here (Figures 2 and 3) were not intended for clinical use with individual patients. Rather they are useful as a means of identifying higher and lower risk sub-groups within the patient population. The prognostic trees themselves should be validated on an independent sample of ALL patients before their reliability and usefulness can be properly judged.
Previous studies have noted the need for clinical guidelines in preventionamanagement of obesity in ALL. 9, 10, 12 Some studies identi®ed`risk factors' for obesity at ®nal height in children treated on older protocols (which included cranial irradiation), notably age at diagnosis, 10 but did not attempt to assess whether these factors were suf®ciently predictive of later obesity to be useful in screening patients for obesity risk. Since these studies focused on obesity at ®nal height, and were based on older treatment protocols, it was necessary to reconsider the issue of risk factors for children treated on more modern protocols and to deal with the fact that excessive obesity can occur early, as demonstrated by the present study. Obesity in ALL is therefore both an`early' and à late' effect, and it occurs even when cranial irradiation is not used in therapy. The present study demonstrated this, with a seven-fold increase in obesity (BMI SDSb2.0) from diagnosis to 1 y after the end of therapy, and large increases in BMI SDS for the cohort during and after therapy ( Table 2) . It is also worth noting that using the BMI as a screening tool for obesity in childhood malignancy is highly speci®c (ie will screen relatively few non-obese children), but has relatively low sensitivity, such that the true prevalence of obesity is higher than that indicated using the BMI in conjunction with simple cut-offs such as BMI SDSb2.0. 27, 28 Any form of screening for obesity in ALL must also take account of`early' obesity in view of the general 3 and ALL-speci®c adverse consequences of obesity. 4 ± 7 If obesity prevention was to be focused on higher risk sub-groups of patients with ALL, the effect of gender on risk would have to be considered. Separate prognostic trees would have to be used for boys and girls, but this does not contradict the present view that the risk of obesity at ®nal height differs between boys and girls. On the basis of the present study, the focus of prevention could be on those children with lower BMI SDS at diagnosis (ie thinner children), who are younger and (in the girls) from groups of lower socioeconomic status. If resources are not limited an approach directed at all patients might be more fruitful, particularly when the other late effects of ALL are considered, notably the`metabolic syndrome'. It is also important to note that identifying children with ALL who show excess weight gain before they are obese is possible using simple measurements (height and weight) made routinely, and simple clinical guidelines for the prevention and management of overweight, based on the BMI, are available. 21 This presents the prospect of prevention of obesity in these patients, which is more likely to be successful than treatment of obesity in the survivors. 3,29 Figure 3 Prognostic tree for change in BMI SDS in 45 girls treated for ALL. Numbers at each tree`branch' represent predicted gain in BMI SDS. Numbers in parentheses: (s.d., n).
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